| Customization: | Available |
|---|---|
| Transport Package: | Drum |
| Specification: | 99% |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Tofacitinib, marketed under the brand name Xeljanz, is an oral Janus kinase (JAK) inhibitor used for the treatment of several autoimmune and inflammatory conditions. JAK inhibitors like tofacitinib work by targeting the JAK pathway, which is involved in the signaling of various cytokines that contribute to inflammation and immune responses.
Mechanism of Action: Tofacitinib specifically inhibits JAK1 and JAK3, two enzymes in the JAK family that play a key role in the signaling of inflammatory cytokines such as interleukin-6 (IL-6), interferons, and others. By inhibiting these enzymes, tofacitinib reduces the activity of the immune system, which helps to control the symptoms of autoimmune diseases.
Indications:
){kind=link}